Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Oct 2023 According to a LEO Pharma media release, efficacy and safety data from this study will be presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress from the 11th to the 14th of October in Berlin, Germany.
18 Mar 2023 Primary endpoint (Change in EASI score from baseline to Week 16) has been met, as per the results presented in the Leo Pharma Media Release.
18 Mar 2023 Results assessing safety and efficacy of LEO 138559 in patients with moderate-to-severe atopic dermatitis, presented at 2023 American Academy of Dermatology (AAD) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com